Market Research

Kinase Inhibitors Market (Type: Non-receptor Tyrosine Kinase Inhibitors, Receptor Tyrosine Kinase Inhibitors, Multikinase Inhibitors, Serine/Threonine Kinase Inhibitors, Protein Kinase C Inhibitors, RHO Kinase Inhibitors and Others; Route of Administratio

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 219 Pages Transparency Market Research Pvt. Ltd. February, 2025 TNPR19910771
Best Price Guarantee
Price from $5,795
Length 219 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date February, 2025
SKU TNPR19910771

Kinase Inhibitors Market – Scope of Report

TMR’s report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kinase inhibitors market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the kinase inhibitors market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kinase inhibitors market profiled in this report.

Key Questions Answered in Global kinase inhibitors Market Report

  • What is the sales/revenue generated by kinase inhibitors across all regions during the forecast period?
  • What are the opportunities in the global kinase inhibitors market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Kinase Inhibitors Market – Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Kinase Inhibitors Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Kinase Inhibitors Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. PESTEL Analysis
5.3. Regulatory Scenario by Key Countries/Regions
5.4. PORTER’s Five Forces Analysis
5.5. Product/Brand Analysis
5.6. Supply Chain Analysis
5.7. Pipeline Analysis
6. Global Kinase Inhibitors Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2020-2034
6.3.1. Non-receptor Tyrosine Kinase Inhibitors
6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
6.3.1.2. BCR-ABL
6.3.1.3. Janus Kinase (JAK) Inhibitor
6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
6.3.1.6. Others
6.3.2. Receptor Tyrosine Kinase Inhibitors
6.3.2.1. VEGFR
6.3.2.2. PDGFR
6.3.2.3. EGFR
6.3.2.4. ALK
6.3.2.5. Others
6.3.3. Multikinase Inhibitors
6.3.4. Serine/Threonine Kinase Inhibitors
6.3.5. Protein Kinase C Inhibitors
6.3.6. RHO Kinase Inhibitors
6.3.7. Others
6.4. Market Attractiveness By Type
7. Global Kinase Inhibitors Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Route of Administration, 2020-2034
7.3.1. Oral
7.3.2. Parenteral & Others
7.4. Market Attractiveness By Route of Administration
8. Global Kinase Inhibitors Market Analysis and Forecasts, By Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2020-2034
8.3.1. Oncology
8.3.1.1. Breast Cancer
8.3.1.2. Leukemia
8.3.1.3. Renal Cancers
8.3.1.4. Lung Cancer
8.3.1.5. Melanoma
8.3.1.6. Colorectal Cancer
8.3.1.7. Others
8.3.2. Inflammatory Disorders
8.3.3. Others
8.4. Market Attractiveness By Application
9. Global Kinase Inhibitors Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Independent Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness By End-user
10. Global Kinase Inhibitors Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Kinase Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2020-2034
11.2.1. Non-receptor Tyrosine Kinase Inhibitors
11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
11.2.1.2. BCR-ABL
11.2.1.3. Janus Kinase (JAK) Inhibitor
11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
11.2.1.6. Others
11.2.2. Receptor Tyrosine Kinase Inhibitors
11.2.2.1. VEGFR
11.2.2.2. PDGFR
11.2.2.3. EGFR
11.2.2.4. ALK
11.2.2.5. Others
11.2.3. Multikinase Inhibitors
11.2.4. Serine/Threonine Kinase Inhibitors
11.2.5. Protein Kinase C Inhibitors
11.2.6. RHO Kinase Inhibitors
11.2.7. Others
11.3. Market Value Forecast By Route of Administration, 2020-2034
11.3.1. Oral
11.3.2. Parenteral & Others
11.4. Market Value Forecast By Application, 2020-2034
11.4.1. Oncology
11.4.1.1. Breast Cancer
11.4.1.2. Leukemia
11.4.1.3. Renal Cancers
11.4.1.4. Lung Cancer
11.4.1.5. Melanoma
11.4.1.6. Colorectal Cancer
11.4.1.7. Others
11.4.2. Inflammatory Disorders
11.4.3. Others
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Independent Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Kinase Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2020-2034
12.2.1. Non-receptor Tyrosine Kinase Inhibitors
12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
12.2.1.2. BCR-ABL
12.2.1.3. Janus Kinase (JAK) Inhibitor
12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
12.2.1.6. Others
12.2.2. Receptor Tyrosine Kinase Inhibitors
12.2.2.1. VEGFR
12.2.2.2. PDGFR
12.2.2.3. EGFR
12.2.2.4. ALK
12.2.2.5. Others
12.2.3. Multikinase Inhibitors
12.2.4. Serine/Threonine Kinase Inhibitors
12.2.5. Protein Kinase C Inhibitors
12.2.6. RHO Kinase Inhibitors
12.2.7. Others
12.3. Market Value Forecast By Route of Administration, 2020-2034
12.3.1. Oral
12.3.2. Parenteral & Others
12.4. Market Value Forecast By Application, 2020-2034
12.4.1. Oncology
12.4.1.1. Breast Cancer
12.4.1.2. Leukemia
12.4.1.3. Renal Cancers
12.4.1.4. Lung Cancer
12.4.1.5. Melanoma
12.4.1.6. Colorectal Cancer
12.4.1.7. Others
12.4.2. Inflammatory Disorders
12.4.3. Others
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Independent Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast By Country/Sub-region, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Kinase Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2020-2034
13.2.1. Non-receptor Tyrosine Kinase Inhibitors
13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
13.2.1.2. BCR-ABL
13.2.1.3. Janus Kinase (JAK) Inhibitor
13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
13.2.1.6. Others
13.2.2. Receptor Tyrosine Kinase Inhibitors
13.2.2.1. VEGFR
13.2.2.2. PDGFR
13.2.2.3. EGFR
13.2.2.4. ALK
13.2.2.5. Others
13.2.3. Multikinase Inhibitors
13.2.4. Serine/Threonine Kinase Inhibitors
13.2.5. Protein Kinase C Inhibitors
13.2.6. RHO Kinase Inhibitors
13.2.7. Others
13.3. Market Value Forecast By Route of Administration, 2020-2034
13.3.1. Oral
13.3.2. Parenteral & Others
13.4. Market Value Forecast By Application, 2020-2034
13.4.1. Oncology
13.4.1.1. Breast Cancer
13.4.1.2. Leukemia
13.4.1.3. Renal Cancers
13.4.1.4. Lung Cancer
13.4.1.5. Melanoma
13.4.1.6. Colorectal Cancer
13.4.1.7. Others
13.4.2. Inflammatory Disorders
13.4.3. Others
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Independent Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast By Country/Sub-region, 2020-2034
13.6.1. China
13.6.2. India
13.6.3. Japan
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Kinase Inhibitors Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2020-2034
14.2.1. Non-receptor Tyrosine Kinase Inhibitors
14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
14.2.1.2. BCR-ABL
14.2.1.3. Janus Kinase (JAK) Inhibitor
14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
14.2.1.6. Others
14.2.2. Receptor Tyrosine Kinase Inhibitors
14.2.2.1. VEGFR
14.2.2.2. PDGFR
14.2.2.3. EGFR
14.2.2.4. ALK
14.2.2.5. Others
14.2.3. Multikinase Inhibitors
14.2.4. Serine/Threonine Kinase Inhibitors
14.2.5. Protein Kinase C Inhibitors
14.2.6. RHO Kinase Inhibitors
14.2.7. Others
14.3. Market Value Forecast By Route of Administration, 2020-2034
14.3.1. Oral
14.3.2. Parenteral & Others
14.4. Market Value Forecast By Application, 2020-2034
14.4.1. Oncology
14.4.1.1. Breast Cancer
14.4.1.2. Leukemia
14.4.1.3. Renal Cancers
14.4.1.4. Lung Cancer
14.4.1.5. Melanoma
14.4.1.6. Colorectal Cancer
14.4.1.7. Others
14.4.2. Inflammatory Disorders
14.4.3. Others
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Independent Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast By Country/Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Type, 2020-2034
15.2.1. Non-receptor Tyrosine Kinase Inhibitors
15.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
15.2.1.2. BCR-ABL
15.2.1.3. Janus Kinase (JAK) Inhibitor
15.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
15.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
15.2.1.6. Others
15.2.2. Receptor Tyrosine Kinase Inhibitors
15.2.2.1. VEGFR
15.2.2.2. PDGFR
15.2.2.3. EGFR
15.2.2.4. ALK
15.2.2.5. Others
15.2.3. Multikinase Inhibitors
15.2.4. Serine/Threonine Kinase Inhibitors
15.2.5. Protein Kinase C Inhibitors
15.2.6. RHO Kinase Inhibitors
15.2.7. Others
15.3. Market Value Forecast By Route of Administration, 2020-2034
15.3.1. Oral
15.3.2. Parenteral & Others
15.4. Market Value Forecast By Application, 2020-2034
15.4.1. Oncology
15.4.1.1. Breast Cancer
15.4.1.2. Leukemia
15.4.1.3. Renal Cancers
15.4.1.4. Lung Cancer
15.4.1.5. Melanoma
15.4.1.6. Colorectal Cancer
15.4.1.7. Others
15.4.2. Inflammatory Disorders
15.4.3. Others
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospital Pharmacies
15.5.2. Independent Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast By Country/Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Route of Administration
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
16.3.1. Boehringer Ingelheim International GmbH
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. Novartis AG
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. AstraZeneca plc
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Pfizer, Inc.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. F. Hoffmann-La Roche Ltd
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Bristol-Myers Squibb Company
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. Bayer AG
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. Johnson & Johnson Service, Inc.
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. Merck & Co., Inc.
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. Takeda Pharmaceuticals
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. Eisai Co., Ltd.
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments
16.3.12. GSK Plc.
16.3.12.1. Company Overview
16.3.12.2. Financial Overview
16.3.12.3. Product Portfolio
16.3.12.4. Business Strategies
16.3.12.5. Recent Developments
16.3.13. Eli Lilly
16.3.13.1. Company Overview
16.3.13.2. Financial Overview
16.3.13.3. Product Portfolio
16.3.13.4. Business Strategies
16.3.13.5. Recent Developments
16.3.14. Alcon
16.3.14.1. Company Overview
16.3.14.2. Financial Overview
16.3.14.3. Product Portfolio
16.3.14.4. Business Strategies
16.3.14.5. Recent Developments

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings